CLM is constructed from bioactive glass, a resorbable implantable material. Bio2 has successfully applied the proprietary CLM process technology to produce a rigid, osteoconductive material with an interconnected porous structure facilitating the ingrowth and remodeling of healthy bone.
Bio2 is focused on developing a number of CLM-constructed products designed for reconstructive surgery of the extremities.
More articles on devices:
Amedica’s 2014 revenue to hit $22M to $24M — 6 things to know
Sonoma Orthopedic Products receives $12M in financing round
THINK Surgical’s surgical system for THA receives FDA approval
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
